Daily Stock Analysis, CRSP, CRISPR Therapeutics AG, priceseries

CRISPR Therapeutics AG. Daily Stock Analysis
Stock Information
Open
88.69
Close
84.69
High
88.88
Low
84.33
Previous Close
88.81
Daily Price Gain
-4.12
YTD High
105.12
YTD High Date
Aug 19, 2020
YTD Low
32.30
YTD Low Date
Mar 16, 2020
YTD Price Change
25.37
YTD Gain
42.77%
52 Week High
105.12
52 Week High Date
Aug 19, 2020
52 Week Low
32.30
52 Week Low Date
Mar 16, 2020
52 Week Price Change
38.74
52 Week Gain
84.31%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
17.90
Mar 10. 2017
21.15
10 Trading Days
18.17%
Link
LONG
Jun 21. 2017
15.04
Jun 29. 2017
15.83
6 Trading Days
5.24%
Link
LONG
Dec 21. 2017
19.58
Feb 1. 2018
36.51
27 Trading Days
86.45%
Link
LONG
May 10. 2018
52.12
May 31. 2018
63.49
14 Trading Days
21.82%
Link
LONG
Jan 4. 2019
30.27
Jan 22. 2019
32.54
11 Trading Days
7.50%
Link
LONG
Jun 27. 2019
45.36
Aug 2. 2019
49.40
25 Trading Days
8.90%
Link
LONG
Oct 23. 2019
39.23
Dec 9. 2019
69.08
32 Trading Days
76.08%
Link
LONG
Apr 8. 2020
44.38
Apr 29. 2020
50.21
14 Trading Days
13.13%
Link
LONG
May 5. 2020
52.00
May 27. 2020
62.29
15 Trading Days
19.79%
Link
LONG
Jul 1. 2020
78.50
Jul 23. 2020
89.11
15 Trading Days
13.52%
Link
Company Information
Stock Symbol
CRSP
Exchange
NasdaqGM
Company URL
http://www.crisprtx.com
Company Phone
6173154600
CEO
Rodger Novak
Headquarters
-
Business Address
BAARERSTRASSE 14, ZUG, SWITZERLAND CH-6300
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001674416
About

CRISPR Therapeutics AG develops gene-based medicines for patients with serious diseases. Its therapeutic molecular level using the breakthrough genome-editing technology called CRISPR-Cas9. The company was founded by Rodger Novak, Emmanuelle Charpentier and Shaun Patrick Foy in 2014 and is headquartered in Basel, Switzerland.

Description

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.